Global Survey Reveals Urgent Gaps in Awareness, Access, and Treatment for Hepatitis D

A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, and critical systemic barriers impeding the global fight against hepatitis delta.

Also known as hepatitis D, hepatitis delta is a severe liver disease affecting an estimated 12 million people worldwide. It occurs in people living with hepatitis B, leads to faster disease progression, and significantly increases the risk of liver cancer and death.

The Hepatitis Delta Global Landscape Survey collected responses from 583 individuals across 102 countries, providing the most comprehensive picture to date of global stakeholder perspectives on awareness, testing, and treatment access around hepatitis delta.

Key Findings:

  • There are pronounced regional variations in reported availability and accessibility of hepatitis delta testing and treatment.
  • Even where hepatitis delta testing and treatment are reported to be available, accessibility remains a significant challenge.
  • Both direct and indirect costs are reported as considerable barriers to equitable access to hepatitis delta treatment and care.
  • There are pronounced gaps in knowledge and awareness of hepatitis delta reported by all stakeholders with pronounced regional variations.
  • Lack of knowledge is reported as the most common barrier to both testing and treatment.
  • A third of respondents did not feel sufficiently informed to identify the barriers to hepatitis delta testing and treatment.
  • HCPs reported low levels of training around hepatitis delta, and most expressed a clear interest in further education.

“These findings highlight an urgent need for coordinated action to scale up hepatitis delta education, diagnosis, and care,” said Cary James, CEO of WHA. “Without informed providers, empowered communities, and accessible health services, millions will remain undiagnosed and untreated.”

Calls to Action:

  • Increase both availability and accessibility of testing and treatment for hepatitis delta in health systems.
  • Address the issues of direct and indirect costs of testing and treatment to increase engagement by communities.
  • Adopt testing policies to follow WHO recommendations on reflex testing for hepatitis delta.
  • Inform people living with hepatitis B of the need to test for hepatitis delta through culturally competent awareness campaigns.
  • Provide more robust training on hepatitis delta to healthcare professionals throughout their career progression.
  • Increase provision of knowledge and awareness programmes for community-based organisations and policymakers.
  • Implement skills-building programmes for community-based organisations so they can better advocate to policymakers and public health officials for greater access to testing, treatment and care.

Download the full report: www.worldhepatitisalliance.org/hepatitis-d-survey

Note to Editors:
For further information or interview requests contact: Cary James, Chief Executive, World Hepatitis AllianceEmail: contact@worldhepatitisalliance.org

About WHA:
The World Hepatitis Alliance is an international network of 400 civil society and community organisations across more than 100 countries. It is dedicated to harnessing the power of people living with viral hepatitis to drive its elimination. At WHA, member organisations are the cornerstone of the alliance, working collaboratively to combat hepatitis through advocacy, capacity building, and awareness-raising efforts. WHA also holds countries accountable to their commitments to elimination, fostering action by partnering with a diverse range of organisations worldwide, from local civil society groups to ministries of health and global institutions. www.worldhepatitisalliance.org

SOURCE: World Hepatitis Alliance

World Hepatitis Summit 2024 Convenes in Lisbon

The World Hepatitis Summit (WHS) 2024 Will Bring Together Global Experts to Discuss the Latest Advances in Hepatitis Prevention, Diagnosis and Treatment

The World Hepatitis Summit (WHS) 2024 convenes in Lisbon from 9 – 11 April and will bring together global experts to discuss the latest advances in hepatitis prevention, diagnosis and treatment.

World Hepatitis Summit 2024
World Hepatitis Summit 2024WHS logo

Policy makers, civil society members, representatives from the private sector, academics and other stakeholders will convene to deliberate and share updates on innovative approaches to increase access to testing, vaccination and treatment services for viral hepatitis. Deliberations will also focus on addressing stigma and discrimination and advocating for funding, with an aim for viral hepatitis elimination by 2030.

At the Summit, the World Hepatitis Alliance (WHA) and The European Centre for Disease Prevention and Control (ECDC) will present findings from a first-of-its-kind report examining levels of stigma and discrimination surrounding people living with hepatitis in Europe. The report finds that half (50%) of those living with hepatitis B and C struggle to tell people about their hepatitis. Around a quarter of people living with hepatitis B and C report they have not told their family (23%) or friends (25%) about their hepatitis.

Eliminating the stigma surrounding hepatitis through the introduction of policies and structural changes has been named as a key factor in hepatitis elimination by the World Health Organization (WHO).

On the opening day of the Summit, WHO will release its 2024 Global Hepatitis Report. It is the first consolidated report on viral hepatitis epidemiology, service coverage and product access, with improved data for action. With information from 187 countries, the report outlines regional perspectives and actionable steps to scale up interventions, emphasising the importance of leveraging lessons from the COVID-19 response. A standalone press release will be issued by WHO on 9 April.

About the World Hepatitis Summit
The World Hepatitis Summit is organised by the World Hepatitis Alliance, with the support of the Ministry of Health of Portugal and co-sponsored by WHO. Its mission is to support countries in meeting the targets needed to eliminate viral hepatitis. It is being held in Lisbon and virtually. More information: http://worldhepatitissummit.org/ and https://www.worldhepatitisalliance.org/.

About Viral Hepatitis
Viral hepatitis is inflammation of the liver caused by a virus. WHO says that the total deaths cause by viral hepatitis, including acute cases, cirrhosis and liver cancer, accounted for 1.1 million deaths globally in 2019. In total, over 350 million people in the world are living with viral hepatitis. Each year, over a million people lose their lives because of conditions related to acute hepatitis and chronic infection that cause liver cancer and cirrhosis.

Contact Information
James Gillies
Communications Contact
james.gillies@worldhepatitisalliance.org
00447932328287

Steve Shaw
Marketing Manager
steve.shaw@worldhepatitisalliance.org

SOURCE: World Hepatitis Alliance (WHA)

.

View the original press release on newswire.com.